Study of Pumitamig with Ipilimumab for first-line advanced liver cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a new drug called pumitamig, either alone or with another drug (ipilimumab), for people with advanced liver cancer that hasn't been treated yet. The goal is to see if these drugs can help shrink or control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have advanced liver cancer that cannot be removed by surgery, confirmed by a biopsy or tissue sample.
- You must be able to take care of yourself and be up and about at least half of the day (ECOG score 0 or 1).
- You must not have had any previous cancer treatment for this advanced liver cancer.
- Your cancer must be measurable on scans (like CT or MRI).
- You must not have a bleeding disorder or take blood thinners that increase your risk of bleeding.
- You must not have had an organ transplant or have an autoimmune disease.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new way of giving immunotherapy drugs for advanced liver cancer that cannot be removed by surgery. The goal is to find the best dose for each patient, which may help control the cancer with fewer side effects.
This trial tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) plus a targeted therapy pill (regorafenib) for people with advanced liver cancer that has progressed after first-line treatment. The goal is to see if this combination can shrink tumors or slow cancer growth.
This trial tests a new combination of two immunotherapy drugs (IBI310 and sintilimab) as a first treatment for advanced liver cancer that cannot be removed by surgery. It aims to see if this combination is safe and works better than current options.
This trial tests a new medicine, PF-08634404, alone or with other treatments for adults with advanced liver cancer that cannot be removed by surgery or has spread. It is for people who have not had prior systemic therapy and have good liver function.
This trial tests a new drug called pumitamig given before surgery to people with early-stage non-small cell lung cancer. It aims to see if pumitamig is safe and tolerable, and might help shrink tumors before they are removed.
This study tests a new drug called pumitamig, given alone or with other treatments, for people with advanced kidney cancer that has spread or cannot be removed. It aims to see if the drug is safe and if it helps shrink tumors.
Hear when a new Hepatocellular Carcinoma (HCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.